|Awarded On||November 02, 2011|
|Title||Chimeric T cells for therapy of Hodgkin Lymphomas and CD30+ Non Hodgkin Lymphomas|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Carlos Ramos|
While Hodgkin Lymphomas (HL) and Non Hodgkin Lymphoma (NHL) may have a good response to chemotherapy and radiation, this treatment has severe toxic/fatal effects and fails in a significant number of patients. We have been developing an alternative approach that does not rely on drugs/radiation, but instead boosts the patient's own immunity to the tumor. We have successfully used this approach in patients with HL and NLH in which a virus (Epstein Barr virus or EBV) is present in the tumor cells. We give these patients their own immune cells called T lymphocytes that we have trained in the laboratory to be effective against the cancer cells. By using this approach we have produced long-lasting...